![](https://www.worldpharmatoday.com/wp-content/uploads/2019/09/FDA.jpg)
GSKs Lung Cancer ADC Earns FDA Breakthrough Designation
The FDA has granted breakthrough status to an antibody-drug conjugate (ADC) that GSK licensed from China’s Hansoh Pharma in a $1.7 billion agreement last year. The pharma firm said that GSK5764227 (GSK’227, formerly known as HS-20093) has been granted the …